InvestorsHub Logo
Followers 114
Posts 2958
Boards Moderated 0
Alias Born 06/28/2014

Re: sigma213 post# 3561

Friday, 09/02/2016 11:37:54 AM

Friday, September 02, 2016 11:37:54 AM

Post# of 5874
Sept 1 SEC 8K filing: REVERSE STOCK SPLIT is IMUC's response to delisting due to <$1:
Quote:
The Company is currently reviewing the deficiency identified in the Notice and has begun the process of preparing a plan of compliance. The Company (IMUC) is considering the option of seeking approval of an amendment to the Company’s certificate of incorporation, which would authorize a reverse stock split, at a Special Meeting of Stockholders.
http://secfilings.nasdaq.com/filingFrameset.asp?FilingID=11576455&RcvdDate=9/1/2016&CoName=IMMUNOCELLULAR%20THERAPEUTICS%2C%20LTD.&FormType=8-K&View=html

From 8K filed 8/22/16: BIG DILUTION@16 cents was reason for LARGE VOLUME + UNDER WATER:
Quote:
Subsequent to June 30, 2016, ImmunoCellular entered into an underwriting agreement with Maxim Group LLC, pursuant to which it sold 34,550,000 shares of common stock, pre-funded warrants to purchase 12,450,000 shares of ImmunoCellular’s common stock and base warrants to purchase 35,250,000 shares of its common stock. The common stock and base warrants were sold at a combined public offering price of $0.16, and the base warrants were approved for listing on the NYSE MKT under the symbol “IMUC.WS.” The pre-funded warrants were sold to certain investors in lieu of common stock less the $0.01 per share exercise price for each pre-funded
warrant. The base warrants have an exercise price of $0.1921 per share. Additionally, ImmunoCellular granted the underwriters a 45 day option to purchase up to an additional 7,050,000 shares of common stock and/or base warrants to purchase 5,287,000 shares of its common stock. On August 12, 2016, the underwriters exercised the option to purchase 4,478,625 of additional base warrants at a price of $0.01266 per base warrant. The gross proceeds from the offering are approximately $7.5 million.
http://secfilings.nasdaq.com/filingFrameset.asp?FilingID=11558588&RcvdDate=8/22/2016&CoName=IMMUNOCELLULAR%20THERAPEUTICS%2C%20LTD.&FormType=8-K&View=html

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=124936031